Natural history and management of hepatitis C infection after liver transplantation.
With almost universal virological recurrence and a projected several-fold increase in HCV-related end-stage liver disease within the next decade, a clear understanding of the natural history of posttransplant HCV infection and optimization of the management of recurrent HCV infection are imperative. This article describes the natural history, risk factors, and current strategies for the amelioration of posttransplant HCV infection.
Charlton
Michael
M
Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. charlton.michael@mayo.edu
Wiesner
Russell
R
D018450:Disease Progression; D016174:Hepacivirus / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000473:pathology / Q000821:virology; D016031:Liver Transplantation; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use
D007136:Immunoglobulins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a